Rationale: Cryptogenic strokes, those of unknown cause, have been estimated as high as 30% to 40% of strokes.
S
troke is the second leading cause of death worldwide, behind heart disease, and is a leading cause of disability. 1 Estimates of cryptogenic stroke, of unknown cause, have been estimated as high as 30% to 40%. 2 Cerebrovascular or peripheral inflammation is a contributory factor when the cause of the stroke is known, as in atherosclerosis, but is often inferred even when no smoking gun can be found. 3 However, there is little experimental evidence. Current animal models use germline mutations or artery stenosis 4 and do not provide etiologic insight.
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Chronic inflammation increases with aging and contributes to cerebrovascular disease, which is a risk factor for stroke. 3 TGF-β (transforming growth factor-β) is a critical mediator in immune/ inflammation homeostasis, 5 and alterations of this pathway are implicated in vascular diseases. 4, 6 We previously reported that deletion of the gene encoding TβRII (TGF-β receptor II) in myeloid cells (Tgfbr2 Myeko ) decreased production of type 2 cytokines and cancer metastasis. 7, 8 However, we show here that this type 1 skewed immune environment resulted in spontaneous stroke with 100% penetrance in C57BL/6 mice at 9 to 15 months of age, corresponding to middle age in humans. Characterization of these mice revealed defects in motor function, an increase in inflammatory cytokines, cerebral endotheliopathy, and ischemic brain lesions. Importantly, a high-fat diet (HFD) accelerated stroke incidence in mice analogous to poor diet as a risk factor for human stroke. Both metformin and methotrexate, which are associated with decreased stroke risk in population studies, as well as anti-TNF (tumor necrosis factor) treatment, delayed stroke occurrence. Our data suggest that Tgfbr2 Myeko mice could be used to model risk factors and prevention of stroke.
Methods
Many experimental approaches were used including assessment of neurological impairment, magnetic resonance imaging, bone marrow transplant, ex vivo and in vitro culture, molecular and cellular biology, immune/inflammation assays, statistical analysis, etc. An expanded Materials and Methods section is available in the Online Data Supplement.
Animal Experiments
All animal protocols were approved by the Animal Care and Use Committee at the National Institutes of Health. Myeloid-specific deletion of Tgfbr2 was accomplished through breeding of Tgfbr2 floxed mice with Lysozyme 2 promoter-driven Cre recombinase (LysM-Cre) mice as reported previously. 7 All experiments used homozygous floxed Tgfbr2 mice and control littermate in a C57BL/6 background. Euthanasia criteria were head tilt, circling behavior, trembling, paresis or paralysis, inability to obtain food or water, or >20% body weight loss. For cytokine array, 6-month-old mice were used. For stroke risk assessment studies (Bio-plex), 8-to 12-month-old prestroke mice were used. For stroke prevention, treatments began at 6 months of age. HFD was initiated at 6 weeks of age. For bone marrow transplants, bone marrow was isolated from mice and injected into the tail vein of irradiated recipient mice.
In Vitro Experiments
Cytokine arrays and Bio-plex assays were done using plasma from mice at indicated ages. Myeloid cells were isolated from peripheral blood of 3-to 6-month-old mice using fluorescence-activated cell sorting for endothelial coculture experiments. RNA was purified using Qiagen columns. Mouse macrophage cell line RAW264.7, with short hairpin RNA-mediated knockdown of Tgfbr2, was used as a surrogate for Tgfbr2
Myeko myeloid cells in Western blot and chromatin immunoprecipitation experiments. Immunofluorescence was performed on frozen sections or cytospun cells from blood.
Results

Neurological Impairment and Spontaneous Stroke in Tgfbr2
Myeko Mice
In the course of breeding mice with myeloid deletion of Tgfbr2 (Tgfbr2   Myeko   ) in a C57BL/6 background, it became apparent that Tgfbr2
Myeko older than 6 months occasionally died of unknown causes. The median lifespan was 12 months, with 0% survival by 20 months of age for both males and females ( Figure 1A) . No mortality was observed in wild type (WT; either Tgfbr2 fl/fl without LysM-cre or LysM-cre alone) or LysMcre, Tgfbr2 fl/+ (Tgfbr2 myeloid heterozygous, Tgfbr2
Myehet ) over the course of the study. Tgfbr2
Myeko mice showed signs of neurological impairment that presented as abnormal limb reflexes when lifted by the tail, head tilt, trembling, hiccups, abnormal gait, paresis or paralysis, and weight loss (Online Figure IA ; Online Movies I through III). No neurological impairment or weight loss was observed in littermate WT or Tgfbr2
Myehet mice. Most Tgfbr2 Myeko mice in the lifespan cohort were euthanized for humane reasons because of above signs. All mice showed signs of neurological impairment at euthanasia. Tgfbr2
Myeko mice showed motor function deficits on the ladder traversal test, where Tgfbr2
Myeko mice had a high number of foot slips, and had a significantly higher ataxia coefficient with Digigait analysis ( Figure 1B Myeko mice had high plasma levels of inflammatory cytokines before stroke and after stroke, similar to what has been observed in poststroke patients. Cerebrovascular inflammation and associated focal breach of the blood-brain barrier was observed before stroke in these mice. Modeling stroke prevention, using metformin (antidiabetic), low-dose methotrexate (anti-inflammatory), and infliximab (anti-TNF antibody), reduced inflammation and delayed stroke occurrence in mice. These data suggest that patients with specific cytokine profiles might benefit from anti-inflammatory treatment for stroke prevention. Tgfbr2
Myeko mice thus provide a valuable tool to investigate the cause and progression of vascular inflammation to cerebral vascular disease to stroke. December 8, 2017
period, suggesting an event-related alteration in motor function rather than progressive neurodegeneration ( Figure 1B) .
Large-vessel occlusion, or decreased blood flow, such as that typically seen in the vascular territory distal to a critical stenosis, was not detected on magnetic resonance angiography (Online Figure II) . Atrial fibrillation, the most common cause of cardioembolic stroke, was not detected on electrocardiograms (data not shown). Rather histological analysis of brains from affected Tgfbr2
Myeko mice revealed neuronal damage, small areas of focal ischemia, similar to human lacunar stroke, 9 and microhemorrhage ( Figure 1C ), as well as decreased cellularity in the olfactory lobes, brain stem or cortex in all affected animals (Online Figure IB) . No lesions were observed in brains from 8-month-old WT and unaffected Tgfbr2 Myeko mice (Online Figure IB) . T2-weighted magnetic resonance imaging showed larger brain lesions ( Figure 1D , upper left) that were consistent with neuronal tissue loss observed on histology ( Figure 1D ). Positive staining for GFAP (glial fibrillary acidic protein) indicated astrogliosis, which is typical in ischemia (Online Figure IC) . Neither amyloid plaques nor demyelination outside of stroke lesions was observed, which excluded neurological diseases comparable with Alzheimer disease and multiple sclerosis (Online Figure ID) . From behavioral and histological findings, the cause of neurological impairment and premature death in Tgfbr2
Myeko mice was attributed to spontaneous stroke.
Bone marrow from Tgfbr2 Myeko mice could recapitulate the phenotype in WT mice, whereas WT bone marrow could Myeko bone marrow causes stroke in WT mice (n=13 for Tgfbr2
Myeko donors, n=4 for WT donors). WT->WT denotes donor->recipient mice. F, WT bone marrow rescues stroke in Tgfbr2
Myeko mice (n=10 per group). For E and F, tick marks are censored subjects (alive at termination of experiment). **P<0.01, ***P<0.001.
rescue the phenotype of Tgfbr2
Myeko mice ( Figure 1E and 1F).
WT mice that received Tgfbr2
Myeko bone marrow exhibited mortality ( Figure 1E ) and brain microhemorrhages (Online Figure IF) 
similar to Tgfbr2
Myeko mice. These data exclude the contribution of brain-residing microglia 10, 11 and other cell types reported to be targets of LysM-cre. 12 Together, these data suggest that deficiency of TGF-β signaling in myeloid cells leads to decreased lifespan because of spontaneous stroke.
Inflammatory Cerebrovascular Lesions in Brains of
Tgfbr2
Risk factors for human stroke were not found in Tgfbr2 Table I ), high cholesterol or triglycerides (Online Table I ), or elevated body weight (data not shown). Atherosclerosis in the heart and aorta was not observed by H&E or oil red O staining on a cereal diet, consistent with no elevation in plasma cholesterol. There also is no evidence for cerebral atherosclerosis (data not shown). Brains of affected mice showed infiltration of lymphocytes and macrophages around the cerebral arteries in areas of the brain otherwise devoid of immune cells (Figure 2A and 2B; Online Figure IIA and IIB). Tgfbr2 Myeko mice, as well as WT mice that received Tgfbr2
Myeko bone marrow, showed narrowed cerebral vessel lumens (Online Figure IIB and IIC) . Some arterial lesions showed fibrotic scars that were consistent with thrombosis, fibrin deposition, vascular occlusion, and recanalization (Online Figure IIB) . Inflamed vascular lesions were not observed in the kidneys, liver, or spleen, consistent with blood chemistry that did not indicate damage to major organs (Online Table I ). This might be analogous to the specific relationship between circulating immune cells and cerebral blood vessels in neurodegenerative diseases such as Alzheimer disease. 13 There was no difference in brain immune cell profile by flow cytometry before stroke (Online Figure IID) . No Evans blue leakage was found in the brain parenchyma of prestroke Tgfbr2
Myeko mice, or in the majority of mice with signs of stroke (Online Figure  IIE) . These studies indicate an unlikely widespread breach of the blood-brain barrier in Tgfbr2
Myeko mice. Recruitment of inflammatory cells to blood vessels in normal brain adjacent to stroke lesions ( Figure 2B ) indicated a possible causal role of vascular inflammation in stroke occurrence. In brains from 6-month-old prestroke Tgfbr2
Myeko mice, there was significant colocalization of immune cells with the vasculature (Figure 2C ). Leakage of fluorescent Dextrans into the brain parenchyma revealed focal breakdown of the bloodbrain barrier in regions of the brain costaining for immune cells, but not in areas of the brain without immune infiltrate ( Figure 2D ). Leakage of fluorescent dextrans was more severe and widespread in mice with signs of stroke. Elevated brain expression of endothelial activation markers, ICAM-1 (intercellular adhesion molecule-1) and VWF (von Willebrand factor), was observed in prestroke Tgfbr2
Myeko mice ( Figure 2E 
and 2F). To further examine whether Tgfbr2
Myeko mice might have enhanced susceptibility for vascular inflammation, femoral arteries of Tgfbr2
Myeko and WT mice were subjected to wire injury in vivo. This model is widely used in cardiovascular studies in mice and produces a significant inflammatory response that is not observed with carotid wire injury.
14 At 13 days post-injury, there was an increase in infiltrating CD45 
Mechanisms of Vascular Inflammation
Proinflammatory cytokines cause vascular damage under pathological conditions. 15 To investigate whether an inflammatory cytokine environment plays a role in stroke cause, cytokines were investigated in plasma from 6-month-old prestroke Tgfbr2
Myeko and WT mice. There was a significant elevation of proinflammatory cytokines such as TNF, CXCL10 (chemokine [C-X-C motif] ligand 10), and CCL2 (chemokine [C-C motif] ligand 2; Figure 3A ; Online Figure IIIA) . Representative type 2 cytokines such as IL-4 (interleukin-4) and IL-10 were not detected in plasma from either WT or Tgfbr2
Myeko mice ( Figure 3A ). This enhanced type 1, and deficient type 2 polarization is also observed in vascular inflammation and atherosclerotic plaque formation. 16, 17 Increased blood TNF is particularly interesting as it occurs with aging, vascular inflammation, and cardiovascular disease. 18 WT mice had TNF levels that fell into a narrow range, whereas many Tgfbr2 Myeko mice had elevated levels ( Figure 3B ). Two mouse macrophage cell lines and 1 human myeloid cell line expressed lower levels of TNF RNA after treatment with TGF-β (Online Figure IIIB) , suggesting that TGF-β signaling in myeloid cells is required for repression of TNF.
TNF is known to cause endothelial cell damage in vitro and in vivo. 18 Unlike WT myeloid cells, Tgfbr2 Myeko myeloid cells caused disruption of adherens and tight junctions of C57BL/6 mouse brain microvascular endothelial cells in coculture, as visualized by fragmented border staining of VE (vascular endothelial)-Cadherin, ZO-1 (Zonula occludens), and occludin ( Figure 3C) . A TNF-neutralizing antibody or deletion of TNF also in myeloid cells prevented endothelial damage mediated by Tgfbr2
Myeko myeloid cells ( Figure 3C ). This result was further validated using human dermal microvascular endothelial cells (Online Figure IIIC) . Increased TNF and increased markers for endothelial damage, ICAM-1, and VCAM-1 (vascular cell adhesion molecule) RNA, were observed in mouse brain microvascular endothelial cells cocultured with Tgfbr2
Myeko myeloid cells, which was prevented by deletion of TNF in Tgfbr2
Myeko myeloid cells ( Figure 3D ). These results suggest a cross talk of myeloid cells with endothelial cells through TNF. Taken together, these data suggest that myeloid-produced TNF because of deficiency of TGF-β signaling is critical for endothelial damage, consistent with roles of TNF in stroke initiation and progression. 19 Transcription factor NF-κB (nuclear factor-κB) is a master regulator of inflammatory programs and is activated in aged hematopoietic stem cells. 20 Active, phosphorylated p65 (encoded by Rela) nuclear translocation was observed in myeloid cells sorted from Tgfbr2
Myeko mice ( Figure 3E ). Blockade of TGF-β signaling in RAW264.7 cells using a TβRI inhibitor increased phosphorylation of p65 and nuclear translocation of p65 and p50 ( Figure 3F ). Of note, the TNF promoter region contains 5 putative NF-κB binding sites (Online Figure  IIID) . Chromatin immunoprecipitation for p65 or POLR2A (RNA polymerase 2 [DNA directed] polypeptide A) showed enrichment of TNF promoter binding by TβRII knockdown in RAW264.7 cells ( Figure 3G ; Online Figure IIIE) . Together, our data suggest that TβRII knockdown activated an NF-κB/ TNF inflammatory program that contributes to the endotheliopathy in Tgfbr2
Myeko mice.
Stroke Risk Assessment and Prevention
The events before stroke are particularly interesting and important in understanding stroke cause and stroke risk assessment, which remain one of the toughest challenges. 21 To compile a stroke risk profile, 32 plasma cytokines were measured from young and old WT, young and old prestroke, and old poststroke Tgfbr2
Myeko mice. Tgfbr2 Myeko poststroke mice showed a unique cytokine profile that overlapped with prestroke mice ( Figure 4A) . A human RNA data set of peripheral blood mononuclear cells from patients 6 months postischemic stroke, 16 who are at high risk for subsequent stroke, 17 revealed increased expression of inflammatory cytokines, including TNF ( Figure 4B ). Ingenuity pathway analysis of significantly altered proinflammatory genes from the human data set revealed striking similarity to our mouse prestroke cytokine signature (Online Figure IV) . This suggests that Tgfbr2
Myeko mice model inflammatory processes important for stroke in human patients.
Spontaneous stroke has been achieved in several mouse models through germline mutation, [22] [23] [24] but is not representative Figure 3 . Increased inflammatory cytokines and mediators resulting from deletion of myeloid-specific TGF-β (transforming growth factor-β) signaling. A, Cytokine antibody array of plasma from 1 male and 1 female 6-mo-old prestroke Tgfbr2 Myeko mice compared with 1 male and 1 female wild type (WT; n=2 for each group). Boxed cytokines are indicated with same color text below. B, TNF (tumor necrosis factor) ELISA of plasma from 6-to 8-mo WT and Tgfbr2
Myeko mixed male and female mice prestroke (n=10 WT and n=20 knockout [ko]). C, Tgfbr2
Myeko myeloid cells cause interruption in adherens junctions and tight junctions between cocultured C57BL/6 mouse brain microvascular endothelial cells. Coculture with peripheral blood myeloid cells (cells) from WT, Tgfbr2
Myeko , or Tgfbr2
Myeko TNF −/− (ko) mice. Some samples were treated with TNF, anti-TNF neutralizing antibody or IgG isotype antibody. Notice disruption in the endothelial junctions with TNF treatment and by Tgfbr2
Myeko myeloid cells. D, C57BL/6 brain microvascular endothelial cells have elevated RNA for markers of endothelial damage (top) and TNF (lower) after coculture with Tgfbr2
Myeko (ko) myeloid cells that can be reduced when myeloid cells lack TNF also (dko, Tgfbr2
Myeko TNF −/− ). E, Increased NF-κB (nuclear factor-κB) transcription factor subunit P65 (encoded by Rela) and active, phosphorylated P65 in myeloid cells from Tgfbr2
Myeko mice. P65 and p-P65 (green), nuclei (blue, Dapi). Shown are representative pictures. F, Increased nuclear NF-κB subunits P65 and P50 (encoded by Nfkb1) and active p-P65 on blockade of TGF-β signaling using a TβR1 (R1) inhibitor. Western blots of nuclear (nu) and cytoplasmic (c) fractions from RAW264. Myeko mice prestroke and following signs of stroke. Heatmap of plasma inflammatory cytokines from Tgfbr2 Myeko (knockout [ko]) young (yo) and older mice prestroke (pre) and after signs of stroke (St), compared with young and older wild-type (WT) mice. Each lane is the average of all mice within each group: young WT and ko (n=4 for each, 6 wk old); old WT (10 mo old, n=4); old ko prestroke (7-11 mo old, n=17); and old ko with stroke (7-12 mo old, n=10). B, Increased inflammatory cytokine RNA in peripheral blood mononuclear cells (PBMC) from patients 6 mo after acute stroke, who are at high risk for subsequent stroke. Heatmap of human data set (GSE22255) from stroke patients, compared with nonstroke controls. Each lane is 1 patient. Sixty-five to 73 in control group are older males in this group that were more similar to the ischemic stroke group. Forty-six to 54 in the ischemic stroke group are younger females that were more similar to the control group. C, High-fat diet (HFD) accelerates stroke occurrence in Tgfbr2
Myeko mice (n=13-17). D, Metformin delays stroke occurrence in Tgfbr2
Myeko mice. Female Tgfbr2 Myeko mice were given metformin in the chow starting at 6 mo of age (n=14), compared with female Tgfbr2
Myeko given chow without metformin (n=14). E, Methotrexate delays stroke occurrence in Tgfbr2 Myeko mice. Male and female Tgfbr2
Myeko mice that received weekly methotrexate injections starting at 6 mo of age (n=10), compared with Tgfbr2 Myeko mice injected with vehicle (n=13). Tick marks on survival curves are censored subjects (alive at termination of experiment). F, Plasma TNF (tumor necrosis factor) levels in mice treated with metformin (Metf) or methotrexate (MTX), control, n=23 males and females; metf, n=6 females; MTX, n=8 males and females. G, Delayed stroke occurrence with anti-TNF therapy. Tgfbr2
Myeko mice were injected with infliximab or saline (control) weekly beginning at 6 to 10 mo of age (n=4-5 females plus 9-10 males per group). Mice in each group are age matched. H, I, Infliximab improves neuromuscular function in Tgfbr2
Myeko mice. H, Time to fall on inverted screen test for mice treated with infliximab (IFX) or saline (Con) for 6 mo. n=4 to 5 females and 9 to 10 males per group. I, Decreased Ataxia coefficient in mice treated with IFX for 8 mo (Digigait analysis, n=6 males per group). Stroke occurrence was assessed by head tilt, abnormal gait, severe trembling, paresis or paralysis, or weight loss of >20% because of severe neurological impairment. J, Schematic hypothesis for inflammatory endotheliopathy and stroke in Tgfbr2
Myeko mice. Tgfbr2 deletion in myeloid cells led to increased production of type 1 inflammatory cytokines including TNF, which is mediated through increased NF-κB (nuclear factor-κB) transcriptional activity. Increased circulating TNF leads to damage of cerebral blood vessels and subsequent recruitment of inflammatory cells to the cerebral endothelium. Increased type 1 and decreased type 2 inflammatory responses lead to endothelial damage, resulting in vascular stenosis/occlusion, and ultimately ischemic stroke. ***P<0.001, **P<0.01, *P<0.05. IL indicates interleukin; and TβR2, TGF-β receptor 2.
of the clinical conditions when specific genetic alterations are not a factor. Tgfbr2
Myeko mice were used to model human stroke risk factors and prevention. HFD, a major stroke risk factor, 25 accelerated stroke occurrence in Tgfbr2 Myeko mice ( Figure 4C ). HFD increased blood cholesterol in both WT and Tgfbr2
Myeko mice to a similar extent, but did not significantly increase blood glucose or blood pressure in either group (Online Figure VA) . Prevention with anti-inflammatory drugs was started at 6 months of age, just before the earliest stroke occurrence, but when Tgfbr2
Myeko mice show increased inflammatory cytokines ( Figure 3A) . Metformin, a drug widely used for diabetes mellitus, and which decreased stroke risk in diabetics in epidemiological studies, 26 delayed stroke occurrence ( Figure 4D ). Treatment with low-dose methotrexate, a drug used to treat autoinflammatory diseases such as rheumatoid arthritis and severe psoriasis, 27 also delayed stroke occurrence ( Figure 4E ). Both methotrexate and metformin treatments led to a significant decrease in plasma TNF ( Figure 4F ). Importantly, anti-TNF therapy with infliximab delayed stroke occurrence in Tgfbr2
Myeko mice and led to improved neuromuscular function in prestroke Tgfbr2 Myeko mice ( Figure 4G through 4I) . Tgfbr2
Myeko mice with wholebody deletion of TNF also showed a trend toward delayed stroke occurrence (Online Figure VB) . Of interest, PTGS2 (prostaglandin-endoperoxide synthase 2, the gene encoding COX2 [cyclooxygenase 2]) was elevated and suggested to be a signaling node in the human stroke risk data set (Online Figure IV) . However, Tgfbr2
Myeko mice given the COX2 inhibitor, celecoxib, in the diet showed significantly accelerated stroke (Online Figure VC) , consistent with the increased risk for stroke with celecoxib use in humans. 28 These data provide evidence that Tgfbr2
Myeko mice can be used to model stroke risk factors and prevention.
Discussion
We provide evidence using a novel mouse model, of a cause and effect relationship between inflammation, and cerebrovascular disease and stroke. In this model, myeloid cells that lack Tgfbr2 create a type 1 polarized inflammatory immune environment characterized by elevated inflammatory cytokines. In Tgfbr2
Myeko mice, stroke leads to decreased motor control, and, in particular, we show gait disturbances, which are a common cause of disability in stroke patients.
Our data suggest that inflammation is required for myeloid-mediated cerebrovascular disease that leads to stroke and as such may be an early event in stroke causation. Our findings are consistent with the recent identification of deficiency of ADA2 (adenosine deaminase 2), an autoinflammatory disease caused by loss-of-function mutations in ADA2, a protein almost exclusively produced and secreted by myeloid cells. Affected children experienced recurrent fever early-onset stroke and small-vessel vasculitis. [29] [30] [31] Human monocytes and macrophages with mutant ADA2 are skewed toward a proinflammatory state, which causes endothelial cell damage in vitro and in vivo. 29 Anti-TNF treatment of these patients leads to dramatic clinical improvement of the inflammatory features and reduction in recurrent strokes. 32 Although there is no mouse homolog of ADA2, deficiency of ADA2 patients provide valuable insight into myeloid cell function, inflammation, and stroke risk. In fact, there is increasing evidence for roles of inflammation in stroke causation. 33, 34 In particular, a recent clinical trial using anti-inflammatory therapy targeting IL-1β led to a significant decrease in strokes in cardiovascular patients with high C-reactive protein. 35 Our studies, together with others, offer insight for cryptogenic strokes, ≈30% of all strokes. Identification of high stroke risk patients without currently known risk factors, such as with a plasma cytokine profile, would allow intervention.
Decreased expression of Tgfbr2 in peripheral blood mononuclear cells with age has been reported recently, 36 and reduced TGF-β signaling was observed in aged hematopoietic stem cells. 37 Mutation or polymorphism in TGFβ pathway genes, TGFB1, TGFBR1, and TGFBR2, is associated with vascular disorders that have high stroke risk and inflammation such as Loeys Dietz syndrome, 6, 38 Kawasaki disease, 39, 40 and Moyamoya disease. 41, 42 TGFBR2 polymorphism is also associated with intracerebral hemorrhage. 43 Genetic attenuation of TGF-β signaling in myeloid cells thus constitutes human relevance and is an experimental approach to investigate inflammation-associated stroke causation. We propose that the consequential upregulation of NF-κB and enhanced production of TNF is 1 significant mechanism, consistent with the association of TNF with vascular diseases, atherosclerosis, and stroke. 15, 18, 19 Anti-TNF therapy seems to be efficacious in prevention of cardiovascular events in rheumatoid arthritis. 44, 45 Anti-TNF therapy has also been shown to decrease motor impairment when given to patients >1 year after stroke, presumably by decreasing persistent neuroinflammation. 46 Comparably, we found that anti-TNF therapy of Tgfbr2
Myeko mice with infliximab delayed stroke occurrence and decreased neuromuscular deficits in Tgfbr2
Myeko prestroke mice. Deletion of TNF in Tgfbr2
Myeko mice also trended toward delayed stroke occurrence, supporting our assertion that TNF is an important factor leading to stroke in Tgfbr2 Myeko mice. However, the immune system is a very complex web of cell types and mechanisms that are intricately entwined. Given the scope of inflammatory cytokine elevation, there may be >1 mechanism or cytokine critical for the stroke phenotype in Tgfbr2
Myeko mice. We have demonstrated the use of Tgfbr2
Myeko mice in modeling inflammation-mediated vascular risk factors for the prevention of stroke. Tgfbr2
Myeko mice showed delayed stroke occurrence with anti-inflammation treatments and accelerated stroke occurrence when adding a risk factor, HFD. Although there are limited data on methotrexate as a prevention for stroke, the CIRT (Cardiovascular Inflammation Reduction Trial) is addressing this question in hopes of shedding light on the inflammatory hypothesis of atherothrombosis. 47 If high stroke risk patients could be identified, such as with a plasma cytokine profile, treatment with drugs identified using Tgfbr2 Myeko mice might prevent or delay strokes, prolong life, and decrease disability.
In summary, we propose that deficiency in myeloid TGF-β signaling activates an NF-κB/TNF inflammatory program leading to cerebral inflammatory endotheliopathy and cerebrovascular inflammation culminating in spontaneous stroke ( Figure 4J ). Tgfbr2
Myeko mice developed smaller lesions more December 8, 2017
closely resembling lacunar strokes, which are thought to result from cerebral vascular lesions, as in Tgfbr2 Myeko mice. 9 We anticipate that our studies provide insight into inflammation and vascular disease-associated stroke causation. Myeloid TGF-β signaling could be exploited for intervention of these diseases.
